Journal article · 2026

From biomarker actionability to surveillance utility in SERENA-6

Man Sun, Dan Zang, Jun Chen

The Lancet Oncology, 27(11), e533 · Published 26 October 2026 · DOI 10.1016/s1470-2045(26)00440-7

View at the publisherCite this paper

In brief

“From biomarker actionability to surveillance utility in SERENA-6” is a 2026 journal article by Man Sun and 2 co-authors, published in The Lancet Oncology. OpenAlex counts 0 citations as of 17 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
References
4
Authors
3

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Sun, M., Zang, D., & Chen, J. (2026). From biomarker actionability to surveillance utility in SERENA-6. The Lancet Oncology, 27(11), e533. https://doi.org/10.1016/s1470-2045(26)00440-7

MLA 9

Sun, Man, et al. “From biomarker actionability to surveillance utility in SERENA-6.” The Lancet Oncology, vol. 27, no. 11, 2026, p. e533. https://doi.org/10.1016/s1470-2045(26)00440-7.

Chicago

Sun, Man, Dan Zang, and Jun Chen. 2026. “From biomarker actionability to surveillance utility in SERENA-6.” The Lancet Oncology 27 (11): e533. https://doi.org/10.1016/s1470-2045(26)00440-7.

Harvard

Sun, M., Zang, D. and Chen, J. (2026) ‘From biomarker actionability to surveillance utility in SERENA-6’, The Lancet Oncology, 27(11), p. e533. doi:10.1016/s1470-2045(26)00440-7.

IEEE

M. Sun, D. Zang, and J. Chen, “From biomarker actionability to surveillance utility in SERENA-6,” The Lancet Oncology, vol. 27, no. 11, p. e533, 2026, doi: 10.1016/s1470-2045(26)00440-7.

BibTeX

@article{sun2026from,
  title     = {{From biomarker actionability to surveillance utility in SERENA-6}},
  author    = {Sun, Man and Zang, Dan and Chen, Jun},
  journal   = {The Lancet Oncology},
  year      = {2026},
  volume    = {27},
  number    = {11},
  pages     = {e533},
  doi       = {10.1016/s1470-2045(26)00440-7},
  url       = {https://doi.org/10.1016/s1470-2045(26)00440-7}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies

  • ESR1 mutations
  • circulating tumor DNA
  • camizestrant
  • first-line endocrine therapy
  • liquid biopsy
  • progression-free survival
  • endocrine therapy resistance

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Sun, M., Zang, D., & Chen, J. (2026). From biomarker actionability to surveillance utility in SERENA-6. The Lancet Oncology, 27(11), e533. https://doi.org/10.1016/s1470-2045(26)00440-7

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Man Sun, Dan Zang, Jun Chen.

What is the DOI of this paper?

10.1016/s1470-2045(26)00440-7, permanently at https://doi.org/10.1016/s1470-2045(26)00440-7. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.